[ad_1]
VACCINE CANDIDATE: AstraZeneca and Oxford University’s corona vaccine trial is ongoing in São Paulo, Brazil, among other locations. The photo was taken on June 24. Photo: Amanda Perobelli / X06790
All testing of the AstraZeneca vaccine, which is being developed in collaboration with the University of Oxford, has been suspended due to illness in a phase 3 study participant in the UK.
Report to Statnews Tuesday night.
The company, which is cited as a leading candidate for developing a vaccine, says the pause is part of the routine when a possible unexplained illness is discovered during research trials.
It will now be investigated whether the participants’ illness is a direct side effect of the vaccine. It is not stated what type of disease or side effect it is, or how serious it is.
“In large studies, the diseases will occur by chance, but they must be considered independently to be carefully controlled,” a company spokesperson told the Financial Times, adding that the case will be investigated as soon as possible so as not to delay the study more than necessary. .
In early June 2020, testing of phase 3 of the vaccine began. It has been tested on up to 30,000 volunteers in the United States, in addition to Brazil, South Africa, and the United Kingdom.
You can read more about the vaccine race in the VG crown special
You have reserved 300 million doses
The EU alliance of which Norway is a member has booked 300 million doses, with the possibility of expanding by 100 million. Norway can also access this through the COVAX global alliance. The United States has ordered at least 300 million doses. It is also one of the vaccines that the UK and Australia are focusing on.
also read
The Norwegian Medicines Agency on the Russian vaccine: we do not know if it works against covid-19
US President Donald Trump has told US voters that a corona vaccine could be ready as early as October, that is, before the November 3 presidential election.
– It may come very soon. You may have a big surprise waiting for you. “I’m sure he will be happy,” Trump said during his press conference at the White House on Monday.
According to sources Economic times has spoken, the British AstraZeneca vaccine is one of the alternatives the United States has on the block for so-called emergency approval.
Also in July, the US President said the US was soon on target with a vaccine:
– A danger to the American people
In the United States, some have expressed concern that work on the vaccine has become too political and that a rushed process will go beyond safety. Democratic vice presidential candidate Kamala Harris told CNN on Sunday that she would be skeptical of a pre-election vaccine and would not trust President Trump’s assurances that it was safe.
Did you bring it with you? Trump and the United States abandon international cooperation on vaccines
White House spokesman Judd Deere says the Trump administration has no goal of speeding up the process.
“The American people can rest assured that an approval will follow the gold standard of safety and testing to ensure that a vaccine or treatment is effective,” he wrote in an email to the Washington Post.
– This false narrative from the media and now from the Democratic vice presidential candidate, which suggests that politics affects approvals, is not only false but is a danger to the American people, he adds.
Pharmaceutical companies promise a safe process
On Tuesday, the heads of nine leading drug companies issued a joint statement, promising that they will not seek approval for the vaccines they develop until they are sure they are safe, after extensive testing in phase three.
One of the signers is the owner of AstraZeneca. The others are Johnson & Johnson, Merck, Moderna, Novavax, Pfizer and Sanofi, Forbes writes.
“We believe this promise will help ensure that the public has confidence in the rigid scientific process required to evaluate and ultimately approve covid-19 vaccines,” the Washington Post said in a statement.
